Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 9/20 | 0.54 |
| ▸ | RAB9A | P51151 | 9/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.45 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17221244 | 0.86 | KDM4E (0.63) | KDM4ETP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16797813 | 0.83 | KDM4E (0.59) | KDM4ETP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1543264 | 0.81 | NPC1 (0.47) | KDM4ETP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL286467 | 0.80 | KDM4E (0.65) | KDM4ETP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16797795 | 0.79 | PIK3CG (0.56) | KDM4ETP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9570213 | 0.79 | KDM4E (0.63) | KDM4ETP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13059011 | 0.79 | KDM4E (0.63) | KDM4ETP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL8814958 | 0.79 | KDM4E (0.68) | KDM4ETP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL9598420 | 0.79 | KDM4E (0.63) | KDM4ETP53NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16424527 | 0.75 | KDM4E (1.00) | KDM4ETP53NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3080114-B1 | FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2019-10-02 | — | — | EP | disclosed |
| US-9890174-B2 | Fused Tricyclic imidazole derivatives as modulators of TNF activity | UCB BIOPHARMA SPRL (BE) | 2018-02-13 | — | — | US | disclosed |
| US-20160304530-A1 | Fused Tricyclic Imidazole Derivatives As Modulators of TNF Activity | UCB PHARMA S.A. (BE) | 2016-10-20 | — | — | US | disclosed |
| EP-3080114-A1 | FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SPRL (BE) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015086527-A1 | FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB BIOPHARMA SPRL (BE) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304530-A1 | Fused Tricyclic Imidazole Derivatives As Modulators of TNF Activity | TNF, TNFRSF1A, TNFRSF9 | KDM4E 3730/4885TP53 460/4885NPC1 3347/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.